Israel - englanti - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 22.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Israel - englanti - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 45 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Israel - englanti - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 7.5 mg - eligard 7.5 mg is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer combination with radiotherapy.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - leuprorelin acetate -

Singapore - englanti - HSA (Health Sciences Authority)

dch auriga singapore - leuprorelin 20.87 mg eqv to leuprorelin acetate - injection, powder, lyophilized, for suspension,extended release - 22.5 mg - leuprorelin 20.87 mg eqv to leuprorelin acetate 22.5 mg

Singapore - englanti - HSA (Health Sciences Authority)

dch auriga singapore - leuprorelin 41.7 mg eqv leuprorelin acetate - injection, powder, lyophilized, for suspension,extended release - 45mg - leuprorelin 41.7 mg eqv leuprorelin acetate 45mg

Singapore - englanti - HSA (Health Sciences Authority)

dch auriga singapore - leuprorelin 6.96 mg eqv leuprorelin acetate - injection, powder, lyophilized, for suspension,extended release - 7.5 mg - leuprorelin 6.96 mg eqv leuprorelin acetate 7.5 mg

Australia - englanti - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.